GHRP-2
Also known as: Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102
GHRP-2 is a synthetic growth hormone secretagogue that stimulates GH release through the ghrelin receptor. It is considered one of the most potent GHRPs for GH stimulation.
Key Findings at a Glance
- • GHRP-2 is generally considered the most potent GHRP for growth hormone stimulation on a per-microgram basis while producing substantially less appetite stimulation than GHRP-6.
- • Despite frequent claims that GHRP-2 deepens sleep, a placebo-controlled study found evidence against a role for the GHRP axis in human slow-wave sleep, even though deep sleep and the nocturnal GH pulse naturally coincide.
- • GHRP-2 maintains its GH-releasing effectiveness in elderly subjects, with only modest age-related decline compared to the dramatic reduction in natural GH secretion seen with aging.
- • GHRP-2 has been formally studied as a diagnostic tool for assessing pituitary GH reserve, giving it a clinical validation path distinct from most research peptides.
GHRP-2 Overview & Molecular Profile
GHRP-2 is a synthetic hexapeptide GH secretagogue and potent GHSR-1a agonist, also known as Pralmorelin. Among the major GHRPs, GHRP-2 achieves the highest GH release per microgram in most studies while producing less appetite stimulation than GHRP-6 and less cortisol elevation than Hexarelin. Human clinical studies document 10–15× GH baseline elevations within 30 minutes. Japan approved Pralmorelin for GH deficiency diagnosis, giving it one of the strongest clinical validation profiles among GHRPs.
Mechanism of Action: Hormonal Signaling & Receptor Binding
GHRP-2 acts as a potent agonist at the ghrelin receptor (GHSR-1a), stimulating growth hormone release from the pituitary. It works synergistically with GHRH analogs through activation of different signaling pathways. GHRP-2 may also have some effects on cortisol and prolactin, though less pronounced than GHRP-6. Its appetite-stimulating effects are moderate compared to GHRP-6.
Pharmacokinetics
GHRP-2 Pharmacokinetics: Plasma Concentration Profile
| Series | Tmax (min) | Peak (Relative Plasma Concentration) | Measured through (min) |
|---|---|---|---|
| IV (intravenous) | 0 | 100 | 90 |
| SC (subcutaneous) | 15 | 48 | 120 |
Half-life (t½): approximately 20 min.
Research-Observed Effects
Potent GH Release
Extensive ResearchResearch consistently demonstrates GHRP-2 (Pralmorelin) as one of the most potent growth hormone secretagogues available for research, producing robust GH elevations through high-affinity binding to the growth hormone secretagogue receptor (GHSR-1a) on pituitary somatotroph cells. Clinical studies document peak plasma GH concentrations of 30-100 ng/mL occurring approximately 15-30 minutes after subcutaneous administration, representing 8-20 fold increases above baseline levels depending on dosage and individual response characteristics. GHRP-2's potency for GH stimulation exceeds that of GHRP-6 on a microgram-per-microgram basis while producing less pronounced side effects on appetite and cortisol, making it particularly valuable for growth hormone deficiency treatment studies. The peptide maintains effectiveness in elderly subjects with diminished natural GH production, demonstrating consistent GH responses that decline only modestly with age compared to younger populations. Research protocols frequently combine GHRP-2 with GHRH analogs such as CJC-1295 or Sermorelin for synergistic growth hormone amplification, with studies showing 2-3 fold greater GH release compared to either compound alone.
IGF-1 Elevation
Extensive ResearchStudies demonstrate significant and sustained elevation of insulin-like growth factor 1 (IGF-1) following GHRP-2-induced growth hormone release, with effects persisting beyond the acute GH peak due to the downstream nature of IGF-1 production in the liver. Research shows IGF-1 increases of 25-75% above baseline within 7-14 days of consistent GHRP-2 administration, with levels stabilizing at elevated plateaus during continued treatment protocols. The IGF-1 elevation mediates many of GHRP-2's anabolic effects including enhanced protein synthesis, improved nitrogen retention, and accelerated muscle recovery optimization following resistance exercise in research models. Studies in growth hormone deficiency models demonstrate normalization of IGF-1 levels with appropriate GHRP-2 dosing, suggesting potential applications in growth hormone replacement therapy research. The relationship between GHRP-2 dosing and IGF-1 response provides researchers with a predictable biomarker for assessing treatment efficacy in various endocrine research applications including age-related hormone decline studies.
Moderate Appetite Effects
Moderate ResearchGHRP-2 produces significantly less appetite stimulation compared to GHRP-6, typically causing mild hunger increases in approximately 30-40% of research subjects compared to the near-universal appetite effects observed with GHRP-6. This reduced ghrelin-mimetic activity at hypothalamic appetite centers makes GHRP-2 particularly suitable for metabolic research studies where hunger confounds would complicate data interpretation. Research indicates GHRP-2's modest appetite effects result from lower intrinsic activity at the orexigenic signaling pathways downstream of GHSR-1a activation compared to its robust GH-releasing potency. The balanced profile between GH stimulation and appetite modulation positions GHRP-2 as an ideal research tool for body composition studies, muscle protein synthesis research, and investigations where maintaining controlled feeding conditions is essential. Studies comparing GHRP family members consistently rank GHRP-2 between Ipamorelin (minimal appetite effects) and GHRP-6 (strong appetite effects) on the spectrum of hunger induction.
Sleep Research
Preliminary ResearchThe relationship between GHRP-2 and sleep is frequently discussed because slow-wave (deep) sleep naturally coincides with the largest nocturnal growth hormone pulse. However, controlled human data do not support the idea that GHRP-2 enhances slow-wave sleep: a placebo-controlled polysomnography study found evidence against a role for the GHRP axis in human slow-wave sleep, despite the temporal correlation between deep sleep and nocturnal GH secretion. Interest remains in clarifying how growth hormone secretagogues interact with sleep architecture—particularly in aging, where both GH secretion and slow-wave sleep decline—but current evidence does not establish GHRP-2 as a sleep-enhancing agent.
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. GHRP-2 is not approved for human use by the FDA or any regulatory agency. This information is provided for research reference only and does not constitute a dosing recommendation.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous | 1–3 mcg/kg (or 100–300 mcg) | 1–3× daily | Peak GH at 15–30 min; standard research dosing |
| Intravenous | 1 mcg/kg | Single dose | Used in GH pituitary reserve diagnostic protocols in Japan |
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness
Van den Berghe G, et al.
European Journal of Endocrinology (1999)
This clinical study investigated how continuous GHRP-2 infusion affects the coordinated release of multiple pituitary hormones including growth hormone, thyroid-stimulating hormone (TSH), and prolactin in patients with prolonged critical illness. Researchers administered GHRP-2 via intravenous infusion and measured hormone levels at frequent intervals to capture pulsatile secretion patterns and cross-hormone relationships. Results demonstrated that GHRP-2 produced robust, synchronized increases in GH release while causing modest elevations in TSH and prolactin through apparent pituitary cross-talk mechanisms. The study revealed that peak GH concentrations occurred within 30 minutes of infusion initiation, with levels 10-15 times above baseline, while TSH and prolactin effects were transient and returned to baseline within 2-3 hours. These findings contributed to understanding GHRP-2's pituitary effects profile and helped establish protocols for clinical applications in growth hormone deficiency assessment and treatment studies.
Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children
Pihoker C, Bowers CY, et al.
Journal of Clinical Endocrinology & Metabolism (1998)
This Phase I clinical study characterized the pharmacokinetics and pharmacodynamics of GHRP-2 in children, providing early human data on the peptide's absorption, clearance, and growth-hormone-releasing activity. Administration produced dose-dependent increases in growth hormone secretion, and the study defined plasma pharmacokinetic parameters supporting practical dosing. Co-authored by GHRP co-discoverer Cyril Bowers, the work helped establish GHRP-2 as a potent and well-tolerated growth hormone secretagogue in humans and informed its later use as a diagnostic agent for assessing pituitary GH reserve.
Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep
Moreno-Reyes R, Kerkhofs M, et al.
American Journal of Physiology (1998)
This placebo-controlled study tested whether the growth-hormone-releasing peptide (GHRP) axis contributes to the regulation of slow-wave (deep) sleep in healthy adults, using polysomnography with concurrent hormone sampling. Contrary to the hypothesis that GHRPs promote deep sleep, the investigators found that GHRP administration did not produce a meaningful enhancement of slow-wave sleep, providing evidence against a causal role for the GHRP axis in human slow-wave sleep. Although nocturnal growth hormone secretion and slow-wave sleep are temporally correlated, the results indicate this association does not reflect a direct GHRP-driven promotion of deep sleep—an important caution against assuming GHRP-2 improves sleep quality.
Comparative Research
Explore in-depth research analyses and comparative studies featuring GHRP-2.
Frequently Asked Questions
Is GHRP-2 more potent than GHRP-6?
Yes, GHRP-2 produces greater GH release per microgram compared to GHRP-6 in most published studies—clinical data show 10–15× baseline GH elevations. Additionally, GHRP-2 produces less appetite stimulation than GHRP-6 (a moderate vs. near-universal hunger response) and has less cortisol and prolactin elevation at standard doses. This combination of high GH potency with fewer off-target effects makes GHRP-2 preferred for research focused on GH/IGF-1 effects without appetite or cortisol confounders.
Has GHRP-2 been approved for any medical use?
Yes. GHRP-2 (under the pharmaceutical name Pralmorelin) is approved in Japan as a diagnostic agent for assessing pituitary GH reserve in adults suspected of GH deficiency. This makes GHRP-2 one of the few GHRPs with actual regulatory approval in any country. It is not approved for therapeutic GH replacement use anywhere. This diagnostic approval provides a higher level of clinical validation than most research peptides.
How does GHRP-2 affect sleep quality?
Despite popular claims that GHRP-2 deepens sleep, the controlled evidence does not support this. A placebo-controlled polysomnography study (PMID: 9612233) found evidence against a role for the growth-hormone-releasing peptide axis in human slow-wave sleep—GHRP administration did not meaningfully increase deep sleep. Slow-wave sleep and the nocturnal GH pulse are temporally correlated because both are driven by overlapping hypothalamic circuits, but that correlation does not mean GHRP-2 itself enhances sleep. GHRP-2 should not be assumed to improve sleep quality based on current human data.
How does GHRP-2 compare to Hexarelin?
Both are highly potent GHRPs, but Hexarelin tends to produce more cortisol and prolactin elevation, and more receptor desensitization (tachyphylaxis) with repeated dosing. GHRP-2 maintains more consistent GH response across repeated administrations and has less pronounced cortisol effects, making it better for ongoing research protocols. Hexarelin has stronger documented cardioprotective effects through direct CD36 receptor activation that is independent of GH release—an effect not well-characterized for GHRP-2.
Can GHRP-2 be used to test pituitary function?
Yes. In Japan, Pralmorelin (GHRP-2) is used as a pituitary function test—intravenous administration allows clinicians to measure peak GH response and assess the pituitary's GH reserve capacity. A robust GH response (typically > 9 ng/mL) suggests an intact somatotroph population, while a blunted response indicates potential GH deficiency. This diagnostic application is more specific to pituitary function than conventional insulin tolerance tests and avoids the hypoglycemia risks of older testing methods.
Does GHRP-2 cause desensitization with repeated use?
Research suggests GHRP-2 causes less receptor desensitization (tachyphylaxis) than Hexarelin with repeated dosing protocols. However, some reduction in GH response can occur with very frequent administration (multiple times daily for extended periods). The mechanism involves downregulation of GHSR-1a at the pituitary and potential increases in somatostatin tone. Spacing doses to allow full receptor recovery (typically 2+ hours between injections) helps maintain response consistency.
What research has studied GHRP-2's effects on body composition?
GHRP-2 studies in GH-deficient adults document improvements in lean body mass (1.5–3 kg over 3–6 months), reductions in visceral adiposity, and improved IGF-1 levels. A 3-month double-blind study in elderly subjects showed increased nitrogen retention and reduced fat mass with 100 mcg three times daily. Effects are GH-dependent and mediated through hepatic IGF-1 production. Body composition changes are generally comparable to exogenous GH administration at equivalent GH elevations—supporting GHRP-2's use in GH-deficiency body composition research.
What is GHRP-2's standard research dosing protocol?
In published human studies, GHRP-2 is typically administered subcutaneously at 100–300 mcg per dose, 1–3 times daily. The most common research protocol is 100 mcg three times daily (morning, midday, evening) with the evening dose timed 30–60 minutes before sleep to amplify nocturnal GH pulsatility. For diagnostic pituitary function testing (Pralmorelin test in Japan), 2 mcg/kg IV is the standardized dose. GHRP-2 is frequently combined with GHRH/CJC-1295 to achieve synergistic GH release.
Related Peptides
View allIpamorelin
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin levels.
GHRP-6
GHRP-6 is a synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor. It was one of the first growth hormone releasing peptides developed.
Hexarelin
Hexarelin is a synthetic growth hormone secretagogue and one of the most potent GHRPs. It has been studied for cardioprotective effects in addition to GH release properties.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) with a Drug Affinity Complex that extends its half-life significantly compared to native GHRH.